| Similar Articles |
|---|
 |
Bio-IT World
June 17, 2004
Mark D. Uehling |
How to Spell Discovery Rapidly combining cosmos of chemical and biological data, Johnson & Johnson's multidisciplinary ABCD platform for drug discovery aims to give scientists access to more information -- and the ability to make better decisions   |
Bio-IT World
November 2005 |
Bridges and Boundaries in Drug Discovery Research Good communication, blurring cultural boundaries, and strong project governance may be as, if not more, important as sweeping technology solutions when it comes to converging discovery and IT and expediting drug development. |
Bio-IT World
November 2006
Kevin Davies |
Building a Bridge Over Pharma with IT More than 100 enthusiastic delegates bridging the full breadth of the drug development pipeline gathered recently for the second annual Bridging Pharma and IT conference. Here are some highlights. |
The Motley Fool
September 17, 2010
James Early |
Today's Buy Opportunity: Johnson & Johnson The case for Johnson & Johnson is very simple: Here's a company that's been around forever, that pays a 3.5% dividend, and that's spread across arguably the most necessary sector (behind water and sewage): health care. |
Bio-IT World
May 19, 2004
John Russell |
Informatics Black Boxes ... Not! Vertex's chief technical officer, discusses informatics' bad reputation, buying vs. building, open-source tools, and ROI on IT. |
Bio-IT World
February 2006
John Russell |
Marvelous Models of Biological Systems Here are highlights from a roundtable discussion with researchers representing academia and pharmaceuticals, as well as executives from modeling technology providers on whether or not Pharma is ready to bet on computational modeling of biological systems. |
Fast Company
March 2014
Adam Bluestein |
Will Johnson & Johnson's New Innovation Centers Point The Way Toward Its Future? To visit the southeastern quadrant of Cambridge, Massachusetts, these days is to witness the rise of a new kind of city -- a glassy, gleaming pharmopolis dedicated to the discovery, development, and marketing of drugs. |
Bio-IT World
March 2006
Mike May |
The Evolving Grid Computing System at J&J Johnson & Johnson is planning to double the size of its grid computing network and the number of applications that run on it by the end of this year, according to company executives. |
Chemistry World
August 22, 2013
Phillip Broadwith |
J&J buys Aragon's prostate cancer arm Hormonally-driven cancer drug discovery specialist Aragon Pharmaceuticals has been bought by Johnson & Johnson. |
Bio-IT World
April 2007
Vicki Glaser |
Software Solutions for Medicinal Chemistry Driven by advances in chemical synthesis, instrumentation, and high-throughput and high-content screening technology, medicinal chemistry's transition from an art to a science is benefiting from a wealth of new software products, spanning both bio- and cheminformatics. |
Bio-IT World
April 15, 2003
Mark D. Uehling |
Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials. |
Information Today
February 26, 2015 |
NISO Releases White Paper on the Future of Library Resource Discovery NISO (National Information Standards Organization) published a white paper, "The Future of Library Resource Discovery," which summarizes the current discovery environment. |
Chemistry World
June 1, 2012
Derek Lowe |
Peace, love and understanding You'd think that the chemists and biologists working in drug discovery would understand each other pretty well by now. You would be wrong about that. |
Bio-IT World
February 2006 |
News Blast Franklin Award... Improved Sensitivity... Discovery Tag Team... NIH Screening Begins... |
Information Today
October 24, 2013 |
NISO's Open Discovery Initiative Releases Recommended Practice Draft This recommended practice from the National Information Standards Organization provides guidelines for content providers and discovery service creators on how to address issues that arise in the use of indexed search as part of library discovery services. |
BusinessWeek
April 23, 2007
Arlene Weintraub |
Under The Weather At J&J Johnson & Johnson's three big products have seen setbacks, with little in sight to replace them. |
Bio-IT World
August 13, 2003
Branca et al. |
Discovery Surges and Tools Deliver Market Compass for Q2 finds consolidation among drug discovery companies continuing, but market caps rising. |
| Knowledge@Wharton |
A New Approach to Valuing Biotech Stocks Enormous swings in biotechnology stock prices during the last few weeks show how difficult it is for investors to value biotech companies. It's important to understand the invisible potential locked up in the organizational structure of biotechnology companies... |
